What patents cover adagrasib, and who owns them?
Adagrasib (Krazati) is a small-molecule KRAS G12C inhibitor. The specific patents that cover it depend on the country and on which part of the product they protect (the compound itself, manufacturing processes, formulations, and related dosing/regimen claims). In practice, ownership and relevant patent families are usually split across the drug’s developer and its licensing partners, and the “active” patents you’ll see in any given market are the ones listed for that jurisdiction.
When do adagrasib patents expire?
Patent expiry for adagrasib varies by jurisdiction because patent term and any extensions are applied separately in each country. In most markets, the key dates come from (1) the earliest priority date in the relevant patent family, (2) any patent term adjustments/extensions, and (3) how regulators account for exclusivity. To determine the exact expiration date for a specific country, you typically need to check that country’s patent register and drug exclusivity records for Krazati/adagrasib.
Can generics or biosimilars enter before adagrasib’s patents expire?
Adagrasib is a brand-name small-molecule drug, so the main competitive pathway is generic entry (not biosimilars). Even if a patent remains in force, generics may be able to launch only if they can address patent barriers through one of the following routes (the exact mechanics depend on the country):
- challenging patents’ validity/enforceability,
- waiting for the last protected patent/exclusivity barrier to clear,
- entering under a regulatory pathway that allows delayed launch for certain patents,
- or designing around specific claims (which may trigger additional litigation).
Why do adagrasib patents keep coming up in generics litigation?
For targeted cancer drugs, later-stage exclusivity battles often center on:
- whether a generic would infringe specific compound or method-of-use claims, and
- whether those claims are invalid (for example, for obviousness or lack of novelty).
If multiple related patents exist in a “family,” challengers may attack a subset while still needing to clear others to launch.
How do combination regimens affect patent coverage for adagrasib?
Adagrasib’s labeling and clinical use can involve combination therapy with other agents. Patents sometimes claim particular combinations or treatment regimens (such as dosing schedules or use in specific disease settings). That can matter because even if the base compound patents narrow down, regimen or combination claims can extend the protection window.
What to check if you need the exact adagrasib patent numbers for a country
To get the precise patent details (publication numbers, assignees, claim scope, and expiry dates), the most reliable sources are the official registers for that market, plus any drug-exclusivity listings:
- national patent office databases for the relevant assignees,
- government drug price/regulatory listings that include patent expiry and “patent linkage” details (where applicable),
- and court dockets if there are active generics challenges.
If you tell me which country (for example, US, EU member state, UK, Canada, Japan, or Australia) and whether you want “compound patents” or “method/regimen patents,” I can narrow to the specific expiry timing and the types of claims that typically govern entry.
Sources
None provided.